الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Focusing on cardiovascular damage as a model of uremic effects, most molecules with potential to affect the function of a variety of cell types within the vascular system are difficult to be removed by conventional hemodialysis. Furthermore, repetitive exposure to cytokine-inducing substances during hemodialysis results in chronic inflammation, which may significantly add to cardiovascular complications.
In our study, we demonstrated that the use of OL-HDF in pediatric patients with end stage renal disease resulted in improvement of the systolic function of the myocardium with mean FS of study group during HD was 35 ± 5.6 % versus 39 ± 6 % during HDF (P= 0.007), This was reflected by the reduction of the frequency of patients with impaired contractility during HD compared to HDF (P= 0.02), despite there was no significant change in the frequency of patients on antifailure treatment (P= 0.27). Also, there was significant improvement in the overall frequency of patients without diastolic dysfunction (n=25) during HDF compared with HD (n=19) (P= 0.003). LVMI remained unchanged all through the study period, and so did MBPI, during HD and OL-HDF (P= 0.73) paying attention to better control of blood pressure in hemodialysis patients.
As contributors to cardiovascular morbidities, the overall frequency of hyperhomocysteinemia was lower during OL-HDF compared to HD (P= 0.006). Predialysis tHcy level was markedly reduced from 15 ± 8 µmol/L during HD to 11.9 ± 4.3 µmol/L during OL-HDF with tendency towards statistical significance (P= 0.06). Also, hs-CRP level was markedly reduced to 3.4 ± 3 µg/ml during OL-HDF compared to 7.9 ± 8.9 during HD (P= 0.01).
Based on these findings we assume that the use of such technique in pediatric hemodialysis is of value in cutting down many of the cardiovascular morbidities commonly encountered in such population.